Imunon (NASDAQ:IMNN) Issues Quarterly Earnings Results

Imunon (NASDAQ:IMNN) issued its quarterly earnings results on Tuesday. The company reported ($1.29) EPS for the quarter, topping analysts’ consensus estimates of ($1.43) by $0.14, Zacks reports. The company had revenue of ($0.73) million during the quarter, compared to the consensus estimate of ($0.73) million.

Here are the key takeaways from Imunon’s conference call:

• OVATION 2 final analysis14.7 months, including a >2?year OS increase for patients receiving PARP inhibitors, which the company says supports IMNN-001 as a potential frontline treatment paradigm shift.
• Phase III OVATION 3 is enrolling ahead of plan with 7 active sites (and ~43 centers in start?up/evaluation), early sites exceeding the assumed 0.3 patients/month (some ~1/month), and a target of ~80 patients in the next 12 months with adaptive interims that could accelerate a BLA timeline.
• The phase II MRD study (30 patients) delivered supportive translational signals—preferential peritoneal macrophage uptake, tumor microenvironment remodeling, durable IL?12/IFN?gamma expression and no dose?limiting toxicities—aligning with OVATION 2 and supporting future label/biomarker work.
• Imunon had $8.8 million in cash as of Dec 31, 2025 and projects runway into the second half of 2026, so the company is actively pursuing equity, ATM/warrant activity and partnerships to fully fund OVATION 3, creating near?term financing and dilution risk.

Imunon Stock Up 1.7%

Shares of IMNN stock opened at $2.99 on Thursday. The business has a fifty day simple moving average of $3.18 and a 200 day simple moving average of $3.90. The company has a market cap of $9.18 million, a P/E ratio of -0.38 and a beta of 2.12. Imunon has a twelve month low of $2.52 and a twelve month high of $41.22.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Imunon in a research report on Thursday, January 22nd. reiterated a “buy” rating on shares of Imunon in a research report on Wednesday, January 7th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $255.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Imunon stock. DRW Securities LLC raised its stake in Imunon, Inc. (NASDAQ:IMNN) by 6.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 58,830 shares of the company’s stock after acquiring an additional 3,803 shares during the quarter. DRW Securities LLC owned approximately 1.92% of Imunon worth $224,000 as of its most recent SEC filing. Institutional investors own 4.47% of the company’s stock.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.